Viral vector gene therapies, which harness modified viruses to deliver genetic material into target cells, offer promising therapeutic potential.
Read MoreBrita Hobmann, EIT
Process Engineer
Los Angeles, CA

Brita Hobmann is a process engineer at CRB with over six years of experience on projects across the United States. Brita is continuing to build her resume with new and exciting projects with a heavy focus in the cell and gene therapy realm, including autologous cell therapy, allogenic cell therapy, somatic stem cells, and viral vectors. Her work has provided our clients with insight on how to better use resources to improve efficiency and works on a wide variety of projects, designing and optimizing bio-manufacturing facilities.
Brita has been published in Bioprocess International, Pharmaceutical Engineering magazine, iSpeak’s blog for ISPE, and CRB Cell and Gene Therapy Horizons report. The current rise in cell and gene therapies and her growing knowledge has provided Brita the opportunity to showcase her ability to deliver value through creative design options.
Brita graduated from the University of Colorado at Boulder with a degree in Chemical and Biological Engineering and a minor in Business.
Insights By Brita

In-house production vs. CDMO: meeting the challenges of commercializing cell and gene therapies
Commercializing cell and gene therapies efficiently requires timely decisions about whether to engage a CDMO or develop internal manufacturing capacity. Sometimes the best solution is to do both.
Read More